Latest Administration News

One Click Group Limited has reported a robust 28% increase in revenue for 2025 alongside a significant expansion in its user base and the rollout of an upgraded cash advance product. The fintech’s strategic focus on growth and innovation sets the stage for a promising 2026.

Besra Gold Inc has updated its Bau Gold Project resource estimate and is intensifying efforts to secure critical mining lease renewals, while restructuring its operations to sharpen capital discipline and technical oversight.

The Calmer Co. International Limited has reported a second consecutive quarter of revenue exceeding $2 million, driven by strong U.S. growth and record monthly sales in December. The company’s strategic focus on wholesale and B2B extract channels underpins its confidence in reaching breakeven this fiscal year.

LCL Resources reported promising high-grade gold-copper-silver assays from trenching in Papua New Guinea and is actively pursuing lower-risk jurisdiction assets while advancing its Colombian option agreement.

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

Mach7 Technologies reports a positive operating cash flow in Q2 FY26, securing its first customer for the new Flamingo Architecture product and advancing key strategic initiatives.

Enlitic, Inc. reported its strongest quarter yet with record contract wins totalling A$4.3 million, alongside a strategic capital raise and new cost-saving measures to fuel growth.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

FAR Limited’s December quarter report highlights robust production from the Sangomar field operated by Woodside Energy, alongside a strategic settlement of a $6 million claim with Woodside. The company ends the quarter with a modest cash balance, positioning itself cautiously for the near term.

Resmed Inc. posted robust Q2 FY2026 results, with revenue climbing 11% to $1.4 billion and a 16% rise in non-GAAP earnings per share, underpinned by strong global demand and operational efficiencies.